NCT03180736 2025-12-19EMN14European Myeloma Network B.V.Phase 3 Completed304 enrolled 19 charts 1 FDA
NCT03412565 2025-04-29A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensJanssen Research & Development, LLCPhase 2 Completed265 enrolled 21 charts 3 FDA
NCT01998971 2025-04-25A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaJanssen Research & Development, LLCPhase 1 Completed240 enrolled 2 FDA
NCT02541383 2025-04-13CassiopeiaIntergroupe Francophone du MyelomePhase 3 Completed1,085 enrolled 22 charts 1 FDA